Across TCGA pan-cancer cohorts, IGHV5-51 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated IGHV5-51 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher IGHV5-51 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGHV5-51 expression acts as an unfavorable survival marker.
COAD and UCEC are the cancer types where IGHV5-51 Mutation most reproducibly stratifies survival.